PT - JOURNAL ARTICLE AU - Ashley E. Kim AU - Elisabeth Brandstetter AU - Chelsey Graham AU - Jessica Heimonen AU - Audrey Osterbind AU - Denise J. McCulloch AU - Peter D. Han AU - Lea M. Starita AU - Deborah A. Nickerson AU - Margaret M. Van de Loo AU - Jennifer Mooney AU - Mark J. Rieder AU - Misja Ilcisin AU - Kairsten A. Fay AU - Jover Lee AU - Thomas R. Sibley AU - Trevor Bedford AU - Janet A. Englund AU - Michael Boeckh AU - Helen Y. Chu AU - on behalf of the Seattle Flu Study Investigators TI - Seattle Flu Study - Swab and Send: Study Protocol for At-Home Surveillance Methods to Estimate the Burden of Respiratory Pathogens on a City-Wide Scale AID - 10.1101/2020.03.04.20031211 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.04.20031211 4099 - http://medrxiv.org/content/early/2020/03/07/2020.03.04.20031211.short 4100 - http://medrxiv.org/content/early/2020/03/07/2020.03.04.20031211.full AB - Introduction While seasonal influenza and other respiratory pathogens cause significant morbidity and mortality each year, the community-based burden of these infections remains incompletely understood. Understanding the prevalence, epidemiology, and transmission dynamics of respiratory pathogen infections among community-dwelling individuals is essential during pandemic and epidemic settings and for developing pandemic-preparedness infrastructure.Methods and Analysis We present the protocol for a novel, city-wide home-based cross-sectional study in the Seattle Metropolitan area, utilizing rapid delivery systems for self-collection of a nasal swab and return to the laboratory for respiratory pathogen testing. All participation takes place electronically, including recruitment, consent, and data collection. Within 48 hours of participants self-reporting respiratory symptoms, a nasal swab kit is delivered to the household via a courier service. Demographic and illness characteristics are collected at the time of sample collection and recovery and behavioral information collected one week later. Specimens are tested in the laboratory for multiple respiratory pathogens, and results are available on a public website for participants.Ethics and Dissemination The study was approved by the University of Washington Institutional Review Board (Protocol #00006181). Results will be disseminated through peer-reviewed publications, talks at conferences, and on the Study Website (www.seattleflu.org).Article SummaryThe findings of this study will inform whether a home-based approach to city-wide respiratory surveillance is possible in epidemic settingsA key strength of this study is that it is conducted across diverse neighborhoods spanning a major metropolitan areaClinical findings may not be generalizable, as they are reliant on self-report (vaccination status, symptoms, healthcare utilization, etc.)Competing Interest StatementHelen Y. Chu receives research support from Sanofi, Cepheid, and Genentech/Roche and is a consultant for Merck and GlaxoSmithKline. Janet Englund receives research support from GlaxoSmithKline, AstraZeneca, and Novavax, and is a consultant for SanofiPasteur and Meissa Vaccines. Ashley E. Kim, Elisabeth Brandstetter, Chelsey Graham, Denise J. McCulloch, Jessica Heimonen, Audrey Osterbind, Peter D. Han, Lea M. Starita, Deborah A. Nickerson, Margaret M. Van de Loo, Jennifer Mooney, Mark J. Rieder, Misja Ilcisin, Kairsten A. Fay, Jover Lee, Thomas R. Sibley, and Trevor Bedford declare no competing interests.Funding StatementThe Seattle Flu Study is funded through the Brotman Baty Institute. The funder is not involved in the design of the study, does not have any ownership over the management and conduct of the study, the data, or the rights to publish.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be accessed only by authorized individuals on the study team. Access to de-identified, aggregated data and analysis code will be publicly available on the study web page (www.seattleflu.org).